Aditxt, Inc. (ADTX)
- Previous Close
2.0500 - Open
2.0600 - Bid --
- Ask --
- Day's Range
1.9700 - 2.0600 - 52 Week Range
1.9450 - 68.0800 - Volume
23,789 - Avg. Volume
359,991 - Market Cap (intraday)
3.347M - Beta (5Y Monthly) --
- PE Ratio (TTM)
-- - EPS (TTM)
-64.8300 - Earnings Date May 20, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Aditxt, Inc., a biotech company, engages in the development and commercialization of technologies that focus on improving the health through monitoring and modulating the immune systems. The company develops AditxtScore that allows individuals to understand, manage, and monitor their immune profiles in order to be informed about attacks on or by their immune system; and Apoptotic DNA Immunotherapy, a nucleic acid-based technology that utilizes an approach that mimics the way the body naturally induces tolerance to its tissues. It also develops ADI-100 for skin grafting, psoriasis, type 1 diabetes, and multiple sclerosis. Aditxt, Inc. has a license agreement with Loma Linda University and Leland Stanford Junior University. The company was formerly known as ADiTx Therapeutics, Inc. and changed its name to Aditxt, Inc. in July 2021. Aditxt, Inc. was incorporated in 2017 and is headquartered in Richmond, Virginia.
www.aditxt.comRecent News: ADTX
Performance Overview: ADTX
Trailing total returns as of 5/28/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ADTX
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ADTX
Valuation Measures
Market Cap
3.38M
Enterprise Value
11.38M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
2.71
Price/Book (mrq)
0.34
Enterprise Value/Revenue
22.47
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-111.69%
Return on Equity (ttm)
-838.07%
Revenue (ttm)
506.44k
Net Income Avi to Common (ttm)
-41.45M
Diluted EPS (ttm)
-64.8300
Balance Sheet and Cash Flow
Total Cash (mrq)
88.67k
Total Debt/Equity (mrq)
82.66%
Levered Free Cash Flow (ttm)
-13.48M